Form 8-K - Current report:
SEC Accession No. 0001193125-23-068397
Filing Date
2023-03-13
Accepted
2023-03-13 06:07:31
Documents
12
Period of Report
2023-03-10
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d408324d8k.htm   iXBRL 8-K 26518
  Complete submission text file 0001193125-23-068397.txt   148057

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA agle-20230310.xsd EX-101.SCH 2845
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE agle-20230310_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE agle-20230310_pre.xml EX-101.PRE 11258
6 EXTRACTED XBRL INSTANCE DOCUMENT d408324d8k_htm.xml XML 3358
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 23725577
SIC: 2834 Pharmaceutical Preparations